Wealthspire Advisors (New York)’s Mereo BioPharma MREO Stock Holding History

Wealthspire Advisors (New York)’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$263K	Buy	+796,036	New	+$342K	﹤0.01%	767
2025 Q4	–	Sell	-1,026	Closed	-$2.11K	–	2175
2025 Q3	$2.11K	Buy	+1,026	New	+$1.89K	﹤0.01%	2597
2022 Q1	–	Sell	-19,276	Closed	-$31K	–	506
2021 Q4	$31K	Buy	+19,276	New	+$38.5K	﹤0.01%	533
2021 Q3	–	Sell	-14,276	Closed	-$45K	–	591
2021 Q2	$45K	Hold	14,276	–	–	﹤0.01%	365
2021 Q1	$48K	Hold	14,276	–	–	﹤0.01%	698
2020 Q4	$51K	Buy	+14,276	New	+$35.8K	﹤0.01%	572
2020 Q2	–	Sell	-14,276	Closed	-$15K	–	441
2020 Q1	$15K	Buy	+14,276	New	+$24.7K	﹤0.01%	556

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $712M AUM

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Wealthspire Advisors (New York)'s MREO Position: Q1 2026 in Review

Wealthspire Advisors (New York) opened a new position in Mereo BioPharma (MREO) in Q1 2026: 796,036 shares worth $263K. The stake represents ﹤0.01% of the portfolio and ranks #767 among its holdings. This is a return to the name: Wealthspire Advisors (New York) previously reported a position in MREO as recently as Q3 2025.

Wealthspire Advisors (New York) first reported a position in MREO in Q1 2020 and has held it in 7 quarters since. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

Wealthspire Advisors (New York) held 796,036 shares of Mereo BioPharma worth $263K as of Q1 2026.
Mereo BioPharma was a new Wealthspire Advisors (New York) position in Q1 2026.
Mereo BioPharma made up ﹤0.01% of Wealthspire Advisors (New York)'s portfolio in Q1 2026, its #767 holding.
Wealthspire Advisors (New York) first reported a position in Mereo BioPharma in Q1 2020 and has held it in 7 quarters since.
63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on Wealthspire Advisors (New York)'s 13F filing for Q1 2026, filed 1 May 2026.